Ceftaroline: Difference between revisions
From IDWiki
No edit summary |
m (Text replacement - " species]]" to "]]") |
||
| Line 8: | Line 8: | ||
*Active against [[MRSA]], [[Staphylococcus epidermidis]], aerobic Gram-negative bacilli (similar to [[ceftriaxone]]) |
*Active against [[MRSA]], [[Staphylococcus epidermidis]], aerobic Gram-negative bacilli (similar to [[ceftriaxone]]) |
||
*Low to moderate activity against [[Enterococcus |
*Low to moderate activity against [[Enterococcus]] |
||
*Not active against [[Pseudomonas |
*Not active against [[Pseudomonas]], ESBL-producers, or AmpC-producers |
||
=== Pharmacokinetics and Pharmacodynamics === |
=== Pharmacokinetics and Pharmacodynamics === |
||
Latest revision as of 02:15, 27 January 2022
Background
Mechanism of Action
- Binds to and inhibits PBP-2a
Spectrum of Activity
- Active against MRSA, Staphylococcus epidermidis, aerobic Gram-negative bacilli (similar to ceftriaxone)
- Low to moderate activity against Enterococcus
- Not active against Pseudomonas, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses in CSF adequately
Dosing
- SSTI: ceftaroline 600 mg IV q12h
- Pneumonia and bacteremia: ceftaroline 600 mg IV q8h
Safety
Adverse Drug Reactions
- Rash, eosinophilia, reversible neutropenia (20% when ≥3 weeks)
